|
Characteristic
|
Whole cohort [cases (%)]
|
Propensity score-matched cohort [cases (%)]
|
|---|
|
Total
|
Cisplatin group
|
Docetaxel group
|
P value
|
Total
|
Cisplatin group
|
Docetaxel group
|
P value
|
|---|
|
Total
|
962
|
737
|
225
| |
448
|
224
|
224
| |
|
Age
| | | |
0.245
| | | |
0.124
|
|
≤ 50 years
|
663 (68.9)
|
515 (69.9)
|
148 (65.8)
| |
311 (69.4)
|
163 (72.8)
|
148 (66.1)
| |
|
> 50 years
|
299 (31.1)
|
222 (30.1)
|
77 (34.2)
| |
137 (30.6)
|
61 (27.2)
|
76 (33.9)
| |
|
Sex
| | | |
0.428
| | | |
0.912
|
|
Male
|
716 (74.4)
|
544 (73.8)
|
172 (76.4)
| |
341 (76.1)
|
170 (75.9)
|
171 (76.3)
| |
|
Female
|
246 (25.6)
|
193 (26.2)
|
53 (23.6)
| |
107 (23.9)
|
54 (24.1)
|
53 (23.7)
| |
|
Histological type (WHO)
|
|
I
|
4 (0.4)
|
3 (0.3)
|
1 (0.4)
|
0.939
|
2 (0.4)
|
1 (0.4)
|
1 (0.4)
|
1.000
|
|
II–III
|
958 (99.6)
|
734 (99.7)
|
224 (99.6)
| |
446 (99.6)
|
223 (99.6)
|
223 (99.6)
| |
|
Clinical T stagea
| | | |
0.337
| | | |
0.278
|
|
T1–T2
|
226 (23.5)
|
171 (23.2)
|
55 (24.4)
| |
114 (25.4)
|
59 (26.3)
|
55 (24.6)
| |
|
T3
|
591 (61.4)
|
461 (62.6)
|
130 (57.8)
| |
268 (59.9)
|
138 (61.6)
|
130 (58.0)
| |
|
T4
|
145 (15.1)
|
105 (14.2)
|
40 (17.8)
| |
66 (14.7)
|
27 (12.1)
|
39 (17.4)
| |
|
Clinical N stagea
| | | |
0.049
| | | |
0.959
|
|
N0
|
91 (9.5)
|
72 (9.8)
|
19 (8.4)
| |
40 (8.9)
|
21 (9.4)
|
19 (8.5)
| |
|
N1
|
524 (54.5)
|
398 (54.0)
|
126 (56.3)
| |
252 (56.3)
|
126 (56.3)
|
126 (56.3)
| |
|
N2
|
297 (30.8)
|
221 (30.0)
|
76 (33.8)
| |
151 (33.7)
|
75 (33.5)
|
76 (33.9)
| |
|
N3
|
50 (5.2)
|
46 (6.2)
|
4 (1.8)
| |
5 (1.1)
|
2 (0.9)
|
3 (1.3)
| |
|
Clinical stagea
| | | |
0.109
| | | |
0.189
|
|
II
|
123 (12.8)
|
85 (11.5)
|
38 (16.9)
| |
80 (17.9)
|
42 (10.2)
|
38 (17.0)
| |
|
III
|
645 (67.0)
|
501 (68.0)
|
144 (64.0)
| |
298 (66.5)
|
154 (68.8)
|
144 (64.3)
| |
|
IV
|
194 (20.2)
|
151 (20.5)
|
43 (19.1)
| |
70 (15.6)
|
28 (12.5)
|
42 (18.7)
| |
|
Pretreatment EBV DNA
| | | |
0.258
| | | |
0.694
|
|
< 4000 copies/mL
|
633 (65.8)
|
492 (66.8)
|
141 (62.7)
| |
286 (63.8)
|
145 (64.7)
|
141 (62.9)
| |
|
≥ 4000 copies/mL
|
329 (34.2)
|
245 (33.2)
|
84 (37.3)
| |
162 (36.2)
|
79 (35.3)
|
83 (37.1)
| |
- WHO World Health Organization, EBV Epstein–Barr virus
- aThe 7th edition of the AJCC/UICC staging system was used for TNM classification
